Analysis Of Cognitive Function And Its Influencing Factors In Patients With Prostate Cancer After Maximal Androgen Blockade Therapy

Objective:To investigate the cognitive function of patients with prostate cancer after maximal androgen blockade therapy and its influencing factors, and to provide a new way for early prevention strategy. Methods:Montreal cognitive assessment(Mo CA), hospital anxiety depression scale(HAD), social support rating scale(SSRS) and self-designed questionnaire were used in 56 cases treated with maximum androgen blockade therapy more than six months and 37 cases who underwent radical prostatectomy treatment of prostate cancer patients with cognitive function test and the observation indexes collection during January 2013 to October 2015. By Mo CA score is divided into 26, divided into cognitive dysfunction group of 40 patients and normal cognitive function group of 53 cases, comparing the observation indexes of two groups of patients, and cognitive function in patients with different treatment of two groups were analyzed, and the changes on the influencing factors of cognitive function in patients with status filtered using multiariable logistic regression analysis. Results:The cognitive dysfunction group and normal group in the proportion of MAB treatment [80%(32/40) vs. 45.3%(24/53)], age(73.7 vs. 73.7 years), the condition of living alone [32.5%(13/40) vs. 13.2%(7/53)], depressive symptoms [87.5%(35/40) vs. 62.3%(33/53)], social support level(32.5 vs. 41.1) and the proportion of testosterone decreased [95%(38/40) vs. 45.3%(24/53)] aspects differences statistically significant(P < 0.05). MAB treatment group compared with radical surgical treatment group, the testosterone level [(0.27±0.15) vs.(12.14±1.86) nmol/L], visual space and executive function(4.18±0.79 vs. 4.54±0.56), attention(4.73±0.99 vs. 5.16±0.79), delayed memory(3.75±1.21 vs. 4.30±1.05) and Mo CA score(26.13±1.48 vs. 27.27±1.39)there is statistically significant difference(P < 0.05). The results of multiple regression analysis showed that age(OR=1.183, 95%CI=1.135~1.223), depressive symptoms(OR=1.092, 95%CI=1.047~1.149), social support(OR=0.897, 95%CI=0.838~0.956), testosterone(OR=2.105, 95%CI=1.369~4.083) were the influencing factors of cognitive dysfunction. Conclusion:The incidence of cognitive dysfunction in patients with prostate cancer after maximal androgen blockade therapy more than six months was higher. Age, depression, social support level and testosterone levels were related to the occurrence of cognitive dysfunction.